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Abstract
Background: The prevalence of invasive fungal infections (IFIs) has increased steadily worldwide in the last few
decades. Particularly, there has been a global rise in the number of infections among immunosuppressed people.
These patients present severe clinical forms of the infections, which are commonly fatal, and they are more
susceptible to opportunistic fungal infections than non-immunocompromised people. IFIs have historically been
associated with high morbidity and mortality, partly because of the limitations of available antifungal therapies,
including side effects, toxicities, drug interactions and antifungal resistance. Thus, the search for alternative
therapies and/or the development of more specific drugs is a challenge that needs to be met. Genomics has
created new ways of examining genes, which open new strategies for drug development and control of human
diseases.
Results: In silico analyses and manual mining selected initially 57 potential drug targets, based on 55 genes
experimentally confirmed as essential for Candida albicans or Aspergillus fumigatus and other 2 genes (kre2 and
erg6) relevant for fungal survival within the host. Orthologs for those 57 potential targets were also identified in
eight human fungal pathogens (C. albicans, A. fumigatus, Blastomyces dermatitidis, Paracoccidioides brasiliensis,
Paracoccidioides lutzii, Coccidioides immitis, Cryptococcus neoformans and Histoplasma capsulatum). Of those, 10
genes were present in all pathogenic fungi analyzed and absent in the human genome. We focused on four
candidates: trr1 that encodes for thioredoxin reductase, rim8 that encodes for a protein involved in the proteolytic
activation of a transcriptional factor in response to alkaline pH, kre2 that encodes for a-1,2-mannosyltransferase and
erg6 that encodes for Δ(24)-sterol C-methyltransferase.
Conclusions: Our data show that the comparative genomics analysis of eight fungal pathogens enabled the
identification of four new potential drug targets. The preferred profile for fungal targets includes proteins
conserved among fungi, but absent in the human genome. These characteristics potentially minimize toxic side
effects exerted by pharmacological inhibition of the cellular targets. From this first step of post-genomic analysis,
we obtained information relevant to future new drug development.
Background
The frequency and diversity of invasive fungal infections
have changed over the last 25 years. The emergence of
less common, but medically important, fungi has
increased, especially in the large populations of immu-
nocompromised patients and of those hospitalized with
serious underlying diseases [1,2]. These patients develop
more severe clinical forms of mycoses, which are com-
monly fatal, and they are more susceptible to infections
by opportunistic fungi than non-immunocompromised
people [3]. The antifungal agents currently available for
the treatment of systemic mycoses include four groups
of drugs: polyenes (amphotericin B), azoles (fluconazole,
itraconazole, ketoconazole, posaconazole and voricona-
zole), echinocandins (caspofungin, anidulafungin, and
micafungin) and flucytosines [4]. Conventional ampho-
tericin B, despite being a broad-spectrum fungicidal
agent with little intrinsic or acquired resistance, is lim-
ited by its serious toxicities and lack of an oral formula-
tion for systemic therapy. In recent years, three lipid
formulations of amphotericin B (amphotericin B lipid
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mal amphotericin B) have been developed and approved
by the Food and Drug Administration (FDA). Although
less nephrotoxic than deoxycholate amphotericin B,
lipid amphotericin B nephrotoxicity still limits treatment
compared to the newer triazoles and echinocandins [5].
The triazoles are the most widely used antifungal agents
and have activity against many fungal pathogens, with
less serious nephrotoxic effects observed than with
amphotericin B. However, the azoles antifungals have
many drug-drug interactions with multiple drug classes
owing to their interference with hepatic cytochrome P-
450 enzymes [6]. Another problem with azoles therapy
is the acquired resistance of many pathogens to these
drugs, which is the most common cause of refractory
infection. Thus, the search for alternative therapies and/
or the development of more specific drugs is a chal-
lenge. Recently, efforts have been devoted to the chemis-
try side of discovering new antifungal agents, including
the development of third-generation azoles or a new
therapeutic class of antifungal drugs, such as echinocan-
dins [7]. Additionally, nanotechnology approaches have
improved the development of innovative products that
reduce side effects by lowering dose administration of
already available drugs, such as amphotericin B nanoen-
capsulated [8-10]. Many advances have been made in
antifungal drug development in the past decade. How-
ever, the search for more specific drugs, in an effort to
overcome the global problem of resistance to antifungal
agents and minimize the serious side effects, is increas-
ingly relevant and necessary.
Currently, drug research and development are expen-
sive and time consuming. An estimated 14 years and an
average of $1.8 billion is the investment required to
develop a new drug that will reach the market [11].
Selecting new molecular targets by comparative geno-
mics, homology modeling and virtual screening of com-
pounds is promising in the process of new drug
discovery. In fact, technological advances over the past
two decades have led to the accumulation of genome-
wide sequence data for many different fungal species. As
the number of sequenced genomes rapidly increases,
searching and comparing sequence features within and
between species has become a part of most biological
inquires [12]. Currently, 183 fungi genomes have been
sequenced, either completely or are in the process of
sequencing, and 40 human pathogenic fungi genomes
have been sequenced. (Data collected on 09/07/2010 in
the following databases: Fungal Genomes, TIGR, Sanger,
Broad Institute and NCBI). Seven of the human patho-
gens are of great importance in systemic mycosis: Can-
dida albicans, Aspergillus fumigatus, Blastomyces
dermatitidis, Coccidioides immitis, Cryptococcus neofor-
mans, Paracoccidioides brasiliensis and Histoplasma
capsulatum, which are strong candidates for post-geno-
mic studies.
Comparative genomics strategy is a useful tool in
identifying potential new drug targets, such as putative
essential genes and/or those affecting the cell viability
that are conserved in pathogenic organisms [13-16]. By
this methodology, ten genes conserved in three bacteria
species (Staphylococcus aureus, Mycobacterium tubercu-
losis and Escherichia coli 0157: H7) were selected as
candidates for an antibacterial drug [14]. Since the
publication of the nematode Brugia malayi complete
genome, Kumar and colleagues [15] conducted a com-
parison analysis between the genomes of B. malayi and
Caenorhabditis elegans a n dw e r ea b l et oi d e n t i f y7 , 4 3 5
orthologs genes, from which 589 were identified as
essential, as well as absent in the human genome, result-
ing in a list of candidate target genes for new drug
development. Recently, Caffrey and colleagues [16] iden-
tified new drug targets in the metazoan pathogen Schis-
tosoma mansoni, the causative agent of Schistosomiasis.
The authors identified 35 orthologs essential genes and
potential drug targets against this human pathogen.
Here we identified potential drug targets applied to
human fungal pathogens using comparative genomics
strategy. Ten genes were present in all pathogenic fungi
analyzed and absent in the human genome. Among
them, four genes (trr1, rim8, kre2 and erg6)w e r e
selected for future research and new drug development.
Two of those genes codify for proteins (TRR1 and
K R E 2 )t h a ts h o w e ds i g n i f i c a nt identity when compared
to templates already deposited in the databank PDB
(Protein Database Bank), which were used to perform
homology modeling of both enzymes. These results
will be used to virtually screen combinatorial libraries,
offering new perspectives on technological development
and innovation of antifungal agents against human
pathogens.
Results and Discussion
Drug target selection
Direct demonstration of A. fumigatus and C. albicans
gene essentiality was achieved using conditional promo-
ter replacement (CPR) [17] and gene replacement and
conditional expression (GRACE) strategies [18], respec-
tively. Therefore, the initial ensemble of genes, experi-
mentally described as essential in C. albicans and/or
A. fumigatus were used to identify 55 orthologs. In addi-
tion, two non-essential genes (kre2 and erg6), but which
are important to cell viability within the host [19,20],
w e r ea d d e dt ot h el i s to fp o s s i b l ed r u gt a r g e t s .T h e
alignments of those 57 sequences against the genome of
the 8 pathogenic fungi P. lutzii, P. brasiliensis isolates
(Pb18 e Pb3), A. fumigatus, B. dermatitidis, C. albicans,
C. immitis, C. neoformans, H. capsulatum confirmed the
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ten conserved genes were selected as drug targets
because they were present in all species analyzed and
were also absent in the human genome, as shown in
Table 1.
Six criteria were used to select the potential targets: 1)
be essential or relevant for fungi survival; 2) be present
in all analyzed pathogens, therefore allowing a broad
spectrum of drug action; 3) be absent in the human
genome, therefore avoiding unwanted side effects; 4) be
preferentially an enzyme and have the potential for
assayability; 5) not be auxotrophic, thereby avoiding
host provision of the necessary substrate for the blocked
pathway; and 6) have a cellular localization potentially
accessible to the drug activity. Applying these criteria,
four potential drug targets were identified: trr1, rim8,
kre2 and erg6 genes. Only trr1 and rim8 are essential
genes, but kre2 and erg6 are involved in cell viability
and survival within the host. In addition, those genes
were also identified as potential drug targets in P. lutzii
isolate Pb01 transcriptome, as described by Felipe and
colleagues [21].
The trr1 is an essential gene that encodes for the cyto-
plasmatic enzyme thioredoxin reductase [22]. This pro-
tein plays a critical role in maintaining the cell redox
status [22] and is part of the complex so-called thiore-
doxin system, which contains thioredoxin (Trx), thiore-
doxin reductase (Trr) and NADPH, protecting cells
against oxidative stress [23]. Thioredoxin reductase is
necessary for the viability of C. neoformans [24] and is
essential for erythrocytic stages in Plasmodium falci-
parum [25]; it also appears to be essential for growth in
S. aureus [26]. S. cerevisiae strain deleted for trr1 gene
is hypersensitive to hydrogen peroxide and high tem-
peratures [27,28].
The rim8 is also an essential gene that encodes for a
protein involved in the proteolytic activation of a tran-
scriptional factor in response to alkaline pH and is
located near the plasma membrane [29]. RIM8 (for
yeasts) or PalF (for filamentous fungi) protein binds
strongly to the C-terminal cytoplasmic tail of the seven
transmembrane domains, the putative pH sensor PalH.
Alignment of protein sequences suggests structural simi-
larity of RIM8 to mammalian arrestins, but the sequence
similarity was restricted to short stretches of amino acid
sequences, mostly corresponding to b-strands in arrestin
crystal structures [30]. The RIM8 protein performs an
essential step in the signaling pathway activating
RIM101, which, in turn, regulates alkaline pH-response.
This pathway is also involved in the activation of the
yeast-to-hyphal transition required for host-pathogen
interaction [31].
The kre2 gene encodes for the enzyme a-1,2-mannosyl-
transferase that is located in the Golgi complex. It has a
short amino-terminal cytoplasmic domain, a hydrophobic
membrane-spanning domain and a large carboxy-terminal
catalytic domain [32]. This enzyme is responsible for the
addition of the a-1,2-linked mannose residues to O-linked
carbohydrates and is also involved in N-linked glycosyla-
tion [33-36]. Cell wall-associated proteins are commonly
glycosylated and defects in this process may result in pro-
tein misfolding, instability, and/or reduced enzymatic
activity [36]. Absence of MNT1p in S. cerevisiae resulted
in the synthesis of truncated O-linked oligosaccharides
and this interfered with the functioning and/or synthesis
of cell wall compounds [33,34]. Mutants of C. albicans
Table 1 Potential target genes selected for new antifungal drug development
Gene Biological process Cytolocalization PDB
template
Organism E-
value
PDB sequence identidy
(%)
trr1 Cell redox homeostasis Cytoplasm 1ITJ Saccharomyces cerevisiae 3e-
115
65
1VDC Arabidopsis thaliana 1e-94 57
aur1 Cellular metabolism Golgi and membrane * * * *
mak5 Ribosome biogenesis Nucleolus 1HV8 Methanocaldococcus
jannaschii
7e-42 30
chs1 Cell wall biogenesis/
degradation
Membrane * * * *
tom40 Protein transport Mitochondrion membrane 2QK9 Homo sapiens 0.8 34
kre6 Cell wall biogenesis/
degradation
Golgi apparatus Membrane 2VY0 Pyrococcus furiosus 6e-4 32
fks1 Cell wall organization/
biogenesis
Membrane 1R1M Neisseria meningitidis 0.3 32
kre2 Protein mannosilation Golgi membrane 1S4N Saccharomyces cerevisiae 6e-96 50
erg6 Ergosterol biosynthesis Endoplasmatic reticulum
membrane
3BUS Lechevalieria
aerocolonigenes
5e-18 32
rim8 pH-response regulator Cytoplasm 3G3L Bacteroides fragilis 3,9 38
*Structure absent in PDB (http://www.rcsb.org/pdb/home/home.do).
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nan, marked reduction in adherence and attenuated viru-
lence [34]. Although CaMNT1p is not essential for
viability, MNT1p-mediated O-glycosylation of proteins of
C. albicans is essential for normal host-fungus interactions
[37].
The erg6 gene encodes for the enzyme Δ-(24)-Sterol
C-methyltransferase that is located in the endoplasmic
reticulum. It shows a transmembrane portion and an
active site positioned toward the cytoplasm [38,39]. This
enzyme catalyzes the attachment of a methyl group act-
ing in a bifurcation point of the ergosterol/cholesterol
biosynthesis pathway [40]. In S. cerevisiae, erg6 mutants
showed alteration in membrane fluidity and permeability
[41,42]. In C. albicans, mutants that do not synthesize
Δ-(24)-Sterol C-methyltransferase showed an increase in
the plasma membrane permeability, resulting in cells
with severely compromised phenotypes [20]. erg6
mutants, in Candida lusitaniae, showed a severe growth
defect and decreased ergosterol content [43].
Conserved domains in protein sequences and
phylogenetic analysis
A multiple protein sequence alignment showed the pre-
sence of conserved domains mainly in the catalytic site of
the four selected candidates (Additional files 2, 3, 4, 5).
The catalytic site of the protein TRR1 contains the four-
amino acid-residue sequence Cys-Ala-Thr-Cys
[44,22,45], and these two highly conserved cysteine resi-
dues (Cys142 and Cys145 in C. albicans) are essential for
its redox activity (Additional file 2). RIM8 protein align-
ments showed that in the C-terminal domain, the residue
Ile-331 of A. nidulans, involved in PalF-PalH receptor
binding, was conserved in all the fungi sequences (it is
located in position Ile-320 in P. brasiliensis). The amino
acid residue Ser-86 of A. nidulans,p r e s e n ti nt h e
N-terminal domain and responsible for PalF-PalH inter-
action and pH signaling, was replaced by the conserved
Cys-75 in P. brasiliensis, B. dermatitidis, H. capsulatum,
Cys-76 in C. immitis and Cys-77 in A. fumigatus (Addi-
tional file 3).
The catalytic site of KRE2 proteins contains the con-
served amino acid residues His312, His377, Asp350 and
Glu318 in C. albicans. If those residues are individually
replaced, in C. albicans, the enzyme activities are fully
abolished [46,47]. Our analysis showed highly conserved
catalytic domains of all the sequences of the analyzed
proteins for all the pathogenic fungi. The domain
YNLCHFWSNFEI, previously described as important to
the catalysis mechanism, was also conserved in all fungi
analyzed (Additional file 4).
The ERG6 protein showed four conserved regions in
several sterol methyltransferase (SMT) proteins, includ-
ing Regions II, III and IV, generally present in AdoMet-
dependent enzymes and, Region I, observed in all SMT
enzymes [48]. Region I, a highly conserved region rich
in aromatic amino acids, contains a signature motif
YEXGWG [49]. The mutation of the amino acid resi-
dues situated in Region I altered the catalytic behavior
of the fungal SMT [50-52]. In addition, specific-site
mutation in Region II and Region III of ERG6 protein
showed that certain residues (Cys128, Gly129, Pro133
and Ala193 in S. cerevisiae) were important to C-methy-
lation activity [52]. All important amino acid residues
for ERG6 protein activity were conserved in all fungi
genomes analyzed (Additional file 5).
The alignments of protein sequences were also used in
phylogenetic studies performed by Bayesian analysis to
construct phylogenetic trees relating TRR1, RIM8, KRE2
and ERG6 orthologs. The phylogenetic trees showed the
evolutionary relationships between the different species
used in this work and separated them in different
groups (Figure 1). P. brasiliensis, B. dermatitidis, H. cap-
sulatum, A. fumigatus and C. immitis were clustered
apart from C. albicans and C. neoformans. The posterior
p r o b a b i l i t yv a l u e sw e r ea d d e dt ot h ep h y l o g e n e t i c
branches and received values near 1, showing the con-
sistency and reliability of these branches. In the four
phylogenetic trees, the P. brasiliensis isolate Pb01 was
separated from the other isolates (Pb3 and Pb18). These
findings are in agreement with Teixeira et al. 2009 [53],
in which 13 single-locus topologies showed that the
genus Paracoccidioides contains two highly divergent
groups. As proposed by Teixeira and colleagues [53],
these results reinforce the existence of two species for
Paracoccidioides genus: P. brasiliensis (Pb18 and Pb3)
and P. lutzii (Pb01).
Homology modeling of TRR1 and KRE2
In the absence of experimentally solved structures, com-
putational methods were used to predict 3D protein
models and provide information regarding protein func-
tions and structures [54]. Homology modeling is effi-
cient in new drug design, from the biological target
conception through new drug discovery [55]. Of the
four selected potential targets obtained from our com-
parative genomic analyses, only TRR1 and KRE2 showed
a reasonable sequence identity to the templates found in
PDB (Table 1). Consequently, we performed the homol-
ogy modeling only for these two proteins.
According to the BLAST search performed on the entire
PDB database, the thioredoxin reductase (TRR1) of P. bra-
siliensis showed good sequence identity with two tem-
plates, specifically 3ITJ (PDB ID) of S. cerevisiae (65%
sequence identity) and 1VDC (PDB ID) of Arabidopsis
thaliana (57% sequence identity). In the case of a-1,2-
mannosyltransferase (KRE2) of P. brasiliensis,o n l yt h e
PDB template 1S4N (PDB ID) of S. cerevisiae showed a
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BLAST alignment between P. brasiliensis TRR1 and KRE2
proteins with the PDB templates as found above, we
manually modified them in order to preserve the second-
ary structures and the correspondence between cysteine
residues (Additional file 6a and 6b).
In these alignments between the target sequences and
template structures, a fragment of the C-terminus
region of TRR1 (Glu325-Leu358) and of the N-terminus
region of KRE2 (Met1-Phe70) did not align. Therefore, a
BLAST search with the fragment sequences was per-
formed to verify if these regions had similarity with pro-
teins deposited in the PDB. No confirmation was found,
so these fragment terminus regions of TRR1 and KRE2
were removed from the models. This was legitimate,
since these fragments are not involved in the active site
of the proteins and should not interfere with the virtual
screening that we intend to perform using these models.
The refinement of the homology models was obtained
through molecular mechanics optimization; the stable
structures of TRR1 and KRE2 are displayed in Figure 2.
Figure 2a shows that the enzyme TRR1 has 9 helices
and 17 sheets. Figure 2b shows that the enzyme KRE2
has 18 helices and 11 sheets.
The TRR1 monomeric protein of S. cerevisiae is com-
posed of two domains that form the binding sites of
NADPH and FAD similar to plants. The FAD molecule
is bound to the S. cerevisiae TRR1 protein and is
Figure 1 Phylogenetic analysis between human pathogenic fungi performed by Bayesian analysis. Phylogenetic trees generated from
Bayesian analysis of the genes trr1 (a), rim8 (b), kre2 (c) and erg6 (d). The length of the vertical lines linking one protein is proportional to the
estimated distance between their sequences. The posterior probability values were added to the phylogenetic branches. Af: Aspergillus fumigatus,
Bd: Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis, Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum,
Pl: Paracoccidioides lutzii, Pb3: P. brasiliensis isolate 3, Pb18: P. brasiliensis isolate 18.
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Gln45, Asn54, Gln136, Asp288 and Gln296. The
NADPH binding domain contains active cysteine resi-
d u e sa n di sl i n k e dt ot h eF A Dd o m a i nb yas h o r t
b-sheet [56,57]. Figure 2a shows the two domains in the
P. brasiliensis TRR1 model.
In KRE2 protein, the catalytic mechanism of the active
site involves nucleophylic substitutions mediated by
acidic amino acid residues and an essential Mn
2+ cofac-
tor. Heterologous expression of site-specific mutants of
C. albicans MNT1 protein in Pichia pastoris confirmed
the nature of a nucleophilic reaction center, where the
two conserved histidines (His292 and His357 in P. brasi-
liensis) that coordinated the metal ion cofactor Mn
2+
and created the reactive nucleophylic center required
the nonprocessing, GDP-mannose-dependent, retaining
glycosyltransferase reaction [46]. However, Lobsanov
and colleagues [47] examined the structure and catalysis
mechanism of S. cerevisiae KRE2 enzyme (1S4N tem-
plate) by crystallography and proposed a novel mechan-
ism for this interaction, and the precise function for the
conserved amino acids was determined by site-direct
Figure 2 The predicted tridimensional structure of TRR1 and KRE2 proteins obtained by homology modeling.T h es t r u c t u r e so fT R R 1
(a) and KRE2 (b) proteins. The a-helix is represented by the color red, the b-sheet is represented by yellow and loops are represented by green.
(a - left panel) The KRE2 active site presents the conserved residues His292, His357, Asp330 and Glu298. (Mutation of these residues abolished
the protein activity in C. albicans.) Additional residues found in the KRE2 active site include Glu216, which interacts with the metal ion Mn
2+ and
creates the reactive nucleophylic center for the glycosyltransferase reaction, and Tyr189, which coordinates the donor and acceptor binding that
allows the transfer of the mannose to the growing oligosaccharide. (b - right panel) The TRR1 protein is composed of two domains that
comprise the binding sites of NADPH and FAD. The NADPH binding domain contains the active Cys145 and Cys148 residues. Other important
residues of the TRR1 active site are Ala151, Val152, Pro153 and Ile154 that form a hydrophobic region in the NADPH binding domain.
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posed mechanism of retaining glycosyltransferases such
as CaMNT1p involves a two-step displacement. The
f i r s ts t e pi n v o l v e sa t t a c ko nt h es u g a ra n o m e r i cc e n t e r
by one of the carboxylates, and then a second carboxy-
late acts as the active site nucleophilic to displace the
GDP from the sugar nucleotide, leading to formation of
a glycosyl-enzyme intermediate. The metal ion Mn
2+ is
coordinated by a direct interaction of the residue gluta-
mate (Glu216 in KRE2 protein of P. brasiliensis)a s
shown in Figure 2b, right panel. Transfer of the man-
nose to the growing oligosaccharide is completed by dis-
placement of the enzyme from the intermediate by the
hydroxyl group of the acceptor [46]; in C. albicans
KRE2 protein, tyrosine (Tyr209) coordinates the donor
and acceptor binding from the N-terminal domain and
plays a role in the catalysis [47].
Conclusions
We reported a comparative genomic strategy to provide
a list of potential antifungal drug targets for the human
pathogenic fungi P. brasiliensis, P. lutzii, A. fumigatus,
B. dermatitidis, C. albicans, C. immitis, C. neoformans
and H. capsulatum. The preferred profile for fungal tar-
gets was proteins conserved among these fungi, but
absent in the human genome, aiming to minimize the
potential toxic side effects exerted by pharmacological
inhibition of the cellular targets. In general, the potential
drug targets were selected following the criteria of
essentiality, presence in all human pathogenic fungi con-
sidered here, absence in humans, be preferentially an
enzyme, not be auxotrophic and have accessible cell
localization.
In silico and manual mining provided four genes as
potential drug targets: trr1 that encodes for thioredoxin
reductase, rim8 that encodes for a protein involved in
the proteolytic activation of a transcriptional factor in
response to alkaline pH, kre2 that encodes for a-1,2-
mannosyltransferase and erg6 that encodes for Δ-(24)-
Sterol C-methyltransferase. The increase in structural
databases allows the satisfactory prediction of structures
by theoretical methods, with advantages over more
costly experimental methods. We performed the homol-
ogy modeling for the potential targets that were identi-
f i e dt oh a v eak n o w n3 Ds t r u c t u r ea n dt h a ts h o w e d
good sequence identity to the templates found in PDB,
TRR1 and KRE2. In the absence of structures solved
experimentally, the available homology modeling tools
were extremely useful for the structural prediction of
the TRR1 and KRE2 proteins. From this first step of
post-genomic analysis, we obtained relevant information
for future technological development. Moreover, these
results are being used to virtually screen chemical
libraries, which are under progress, generating new per-
spectives on technological development and innovation
of antifungal agents to these human pathogens.
Methods
Comparative analysis of human pathogenic fungi
genomes and drug target selection
The identification of potential drug targets was based on
55 genes experimentally confirmed as essential for Can-
dida albicans [17] or Aspergillus fumigatus [18]. In
these cases, the genes were experimentally confirmed as
essential and represent a large spectrum of biological
functions, such as cellular metabolism, cell wall organi-
zation and biogenesis, ergosterol biosynthesis, ribosomal
biogenesis and post-translational modification of protein
[17,18]. Other 2 genes (kre2 and erg6) were added to the
initial screening since they were described as potential
drug targets [21].
The 57 gene sequences of were retrieved from the
GenBank databases (http://www.ncbi.nlm.nih.gov/) and
were used to screen the P. brasiliensis Pb01 transcrip-
tome database (https://helix.biomol.unb.br/Pb/) using
blastn. The sequences of Paracoccidioides lutzii isolate
Pb01 were not applied as a filter since all 57 genes were
present and expressed in its genome/transcriptome.
Subsequently, the presence of these genes in the 2 iso-
lates of P. brasiliensis (Pb3 and Pb18) was confirmed.
Using the isolate Pb01 sequence, released by Broad
Institute (http://www.broad.mit.edu/), the orthologs
search in other pathogenic fungi (A. fumigatus Af293,
B. dermatitidis ER3, C. albicans WO1, C. immitis
H538.4, C. neoformans serotype B, H. capsulatum
NAm1) and human genome was completed using blastx
because we have focused in the development of a new
antifungal not only for the Paracoccidioides species but
for all medically important fungi. The cut-off estab-
lished for determining the presence of an ortholog was
a maximum E-value of 0.00001 (1e-5). A manual cura-
tion was performed to select the potential drug targets
following the criteria of essentiality, be present in
pathogenic fungi, be absent in humans, be preferentially
an enzyme, not be auxotrophic and have accessible cell
localization.
Multiple alignments of the orthologs genes and
phylogenetic analysis
Sequences were aligned by the ClustalW using dynamic
programming and hierarchical methods [58] available in
the BioEdit software [59]. The program identified con-
served regions in the protein sequences between ortho-
logs target genes by multiple sequence alignments.
The sequences were also used for phylogenetic analy-
sis by Bayesian inference using Mr. Bayes software,
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were considered missing data and coded in terms of
presence or absence. The amino acid substitution model
selected was JTT [61]. The Markov Chain Monte Carlo
(MCMC) was initiated from a random tree and pro-
cessed for 1000000 generations; sample trees were
retrieved every 1000 generations. Log-likelihood values
were plotted against the generation number, and the
first 25% of samples were discarded (”burn-in“). The
remaining samples were used to determine the distribu-
tion of posterior probability values. Phylogenetic trees
were produced with the help of the Treeview and Fig-
tree 1.0 software.
Protein structure prediction
There is no crystallographic structure presently avail-
able for TRR1 and KRE2 of P. brasiliensis and also for
the other pathogenic fungi. Therefore, the 3D struc-
tures of TRR1 and KRE2 of P. brasiliensis were con-
structed by homology modeling based on known
structures with high percentage of identity in amino
acid sequences. We have initially modeled P. brasilien-
sis proteins but it will be similar for the other patho-
genic fungi since the sequences of the proteins are
highly conserved. The known template structures were
searched in the PDB. There were two templates for
TRR1 protein: 3ITJ (PDB ID) of S. cerevisiae and
1VDC (PDB ID) of A. thaliana. There was one tem-
plate for KRE2 protein: 1S4N (PDB ID) of S. cerevisiae.
The templates structures for ERG6 and RIM8 showed
low sequence identity, then not allowed the construc-
tion of 3D structures for these proteins by molecular
modeling. The amino acid residue sequences of TRR1
and KRE2 were compared with the primary sequences
of the structures deposited in the PDB using the
BLAST program. The homologous sequences allowed
the construction of a 3D model of TRR1 and KRE2
using the homology module of the Insight II software
package (Biosym/MSI, San Diego, Accelrys Inc. 2001).
Briefly, the target sequences were aligned with the
template structures, and coordinates from the tem-
plates were transferred to the targets TRR1 and KRE2.
For model optimization, the backbone atoms of the
structures were initially frozen and only the side chains
were allowed to move for a selective minimization by
conjugate gradient method. A second selective minimi-
zation, also by conjugate gradient method, was per-
formed with only atoms of the complementary
determining region (CDR) loops moving. The last
minimization was performed by Steepest-descent
method with all atoms of the structure relaxed, result-
ing in whole, refined 3D structures. The molecular
visualization was performed by PyMOL open-source
software version 0.99rc6 (Delano Scientific LLC, 2006).
Additional material
Additional file 1: Essential genes found in C. albicans and/or
A. fumigatus and orthologs in other human pathogenic fungi.
Additional file 2: Amino acid alignment between conserved protein
residues of TRR1, in the human pathogenic fungi. Amino acid
sequence analysis of TRR1 protein. Af: Aspergillus fumigatus, Bd:
Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis,
Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pb01:
Paracoccidioides brasiliensis isolate 01, Pb3: P. brasiliensis isolate 3, Pb18:
P. brasiliensis isolate 18. Positions of identity are indicated with asterisks,a
semicolon indicates conserved substitutions, and a dot shows a semi-
conservative substitution.
Additional file 3: Amino acid alignment between conserved protein
residues of RIM8, in the human pathogenic fungi. Amino acid
sequence analysis of RIM8 protein. Af: Aspergillus fumigatus, Bd:
Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis,
Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pb01:
Paracoccidioides brasiliensis isolate 01, Pb3: P. brasiliensis isolate 3, Pb18:
P. brasiliensis isolate 18. Positions of identity are indicated with asterisks,a
semicolon indicates conserved substitutions, and a dot shows a semi-
conservative substitution.
Additional file 4: Amino acid alignment between conserved protein
residues of KRE2, in the human pathogenic fungi. Amino acid
sequence analysis of KRE2 protein. Af: Aspergillus fumigatus, Bd:
Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis,
Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pb01:
Paracoccidioides brasiliensis isolate 01, Pb3: P. brasiliensis isolate 3, Pb18:
P. brasiliensis isolate 18. Positions of identity are indicated with asterisks,a
semicolon indicates conserved substitutions, and a dot shows a semi-
conservative substitution.
Additional file 5: Amino acid alignment between conserved protein
residues of ERG6, in the human pathogenic fungi. Amino acid
sequence analysis of ERG6 protein. Af: Aspergillus fumigatus, Bd:
Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis,
Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pb01:
Paracoccidioides brasiliensis isolate 01, Pb3: P. brasiliensis isolate 3, Pb18:
P. brasiliensis isolate 18. Positions of identity are indicated with asterisks,a
semicolon indicates conserved substitutions, and a dot shows a semi-
conservative substitution.
Additional file 6: Manual alignments performed between P.
brasiliensis proteins and the PDB templates. (a) TRR1 protein and
templates 3ITJand 1VDC. The boxes represent the template regions that
were used as references for the homology modeling of TRR1 protein. In
the alignment between TRR1 protein and the templates, the big boxes
indicate that the 1VDC template was used as reference and the small
box indicates that the reference was the 3ITJ template. Considering the
global alignment, 3ITJ is the best template to use as a reference to
perform the homology modeling of P. brasiliensis TRR1 protein. However,
some regions of the 1VDC template present identical amino acids to P.
brasiliensis TRR1 protein, and those are different in the 3ITJ template. The
following colors represent amino acids: white (identical amino acids
between TRR1 protein and the two templates), green (identical amino
acids between TRR1 protein and 1VDC template), red (identical amino
acids between TRR1 protein and 3ITJ template), orange (unique amino
acids in 3ITJ template), dark blue (unique amino acids in 1VDC template),
and light blue (unique amino acids in TRR1 protein). The cysteine
residues that form the disulfide bonds are conserved between TRR1
protein and the two templates. (b) KRE2 protein and templateIS4N. The
boxes represent the template regions that were used as references for
the homology modeling of KRE2 protein. In the alignment between KRE2
protein and the 1S4N template, the boxes indicate the regions that were
used as references for 3D structure construction of KRE2. The following
colors represent amino acids: white (identical amino acids between KRE2
protein and the template), purple (similar amino acids between KRE2
protein and the template), red (unique amino acids in KRE2 protein), and
light blue (unique amino acids in 1S4N template). The cysteine residues
that form the disulfide bonds are conserved between KRE2 protein and
the template.
Abadio et al. BMC Genomics 2011, 12:75
http://www.biomedcentral.com/1471-2164/12/75
Page 8 of 10Acknowledgements
The authors gratefully acknowledge the Brazilian Agencies CNPq (Conselho
Nacional de Desenvolvimento Científico e Tecnológico) and FAP-DF
(Fundação de Apoio a Pesquisa do Distrito Federal) for financial support.
Author details
1Department of Cellular Biology, University of Brasília, Brasília, Brazil.
2Embrapa - Genetic Resources and Biotechnology, Brasília, Brazil.
3Lorrain
Laboratory of Computing Research and its Applications, University Henri
Poincaré-Nancy I, Nancy, France.
Authors’ contributions
AA, NM, MF and EK planned and designed the study, developed the
experiments and completed the data analysis, wrote the main draft of the
paper and supported the preparation of the figures and tables. BM
participated in the homology modeling experiments and helped in the
manuscript editing. MT participated in the phylogenetic analysis. All authors
read and approved the final manuscript.
Received: 26 August 2010 Accepted: 27 January 2011
Published: 27 January 2011
References
1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD,
Warnock DW: Trends in mortality due to invasive mycotic diseases in the
United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
2. Alvez F, Figueras C, Roselló E: Emerging invasive fungal infections. An
Pediatr (Barc) 2010, 73:52.e1-52.e6.
3. Sable CA, Strohmaier KM, Chodakewitz JA: Advances in antifungal therapy.
Annu Rev Med 2008, 59:361-379.
4. Chapman SW, Sullivan DC, Cleary JD: In search of the holy grail of
antifungal therapy. Trans Am Clin Climatol Assoc 2008, 119:197-215.
5. Moen MD, Lyseng-Williamson KA, Scott LJ: Liposomal amphotericin B: a
review of its use as empirical therapy in febrile neutropenia and in the
treatment of invasive fungal infections. Drugs 2009, 69:361-92.
6. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG,
Verweij PE, Burger DM: Clinical relevance of the pharmacokinetic
interactions of azole antifungal drugs with other coadministered agents.
Clin Infect Dis 2009, 48:1441-58.
7. Fera MT, La Camera E, De Sarro A: New triazoles and echinocandins:
mode of action, in vitro activity and mechanisms of resistance. Expert
review of anti-infective therapy 2009, 7:981-998.
8. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of
amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998,
27:603-18.
9. Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT:
Comparison of the physicochemical, antifungal, and toxic properties of
two liposomal amphotericin B products. Antimicrob Agents Chemother
2008, 52:259-268.
10. Amaral AC, Bocca AL, Ribeiro AM, Nunes J, Peixoto DL, Simioni AR,
Primo FL, Lacava ZG, Bentes R, Titze-de-Almeida R, Tedesco AC, Morais PC,
Felipe MS: Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and
dimercaptosuccinic acid (DMSA) nanoparticles against
paracoccidioidomycosis. J Antimicrob Chemother 2009, 63:526-533.
11. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR,
Schacht AL: How to improve R&D productivity: the pharmaceutical
industry’s grand challenge. Nat Rev Drug Discov 2010, 9:203-14.
12. Jung K, Park J, Choi J, Park B, Kim S, Ahn K, Choi J, Choi D, Kang S, Lee YH:
SNUGB: a versatile genome browser supporting comparative and
functional fungal genomics. BMC Genomics 2008, 9:586.
13. Janaki C, Joshi RR: Accelerating Comparative Genomics Using Parallel
Computing. In Silico Biology 2003, 3:429-440.
14. White TA, Kell DB: Comparative genomic assessment of novel broad-
spectrum targets for antibacterial drugs. Comp Funct Genomics 2004,
5:304-327.
15. Kumar S, Chaudhary K, Foster JM, Novelli JF, Zhang Y, Wang S, Spiro D,
Ghedin E, Carlow CKS: Mining Predicted Essential Genes of Brugia malayi
for Nematode Drug Targets. PLoS ONE 2007, 2:e1189.
16. Caffrey CR, Rohwer A, Oellien F, Marhöfer RJ, Braschi S, Oliveira G,
McKerrow JH, Selzer PM: A comparative chemogenomics strategy to
predict potential drug targets in the metazoan pathogen, Schistosoma
mansoni. PLoS One 2009, 4:e4413.
17. Roemer T, Jiang B, Davison J, Ketela T, Veillette K, Breton A, Tandia F,
Linteau A, Sillaots S, Marta C, Martel N, Veronneau S, Lemieux S,
Kauffman S, Becker J, Boone C, Bussey H: Large-scale essential gene
identification in Candida albicans and applications to antifungal drug
discovery. Molecular Microbiology 2003, 50:167-181.
18. Hu W, Sillaots S, Lemieux S, Davison J, Kauffman S, Breton A, Linteau1 A,
Xin C, Bowman J, Becker J, Jiang B, Roemer T: Essential gene identification
and drug target prioritization in Aspergillus fumigates. PLoS pathogens
2007, 3:e24.
19. Buurman ET, Westwater C, Hube B, Brown AJ, Odds FC, Gow NA: Molecular
analysis of CaMnt1p, a mannosyltransferase important for adhesion and
virulence of Candida albicans. Proc Natl Acad Sci USA 1998, 95:7670-5.
20. Jensen-Pergakes KL, Kennedy MA, Lees ND, Barbuch R, Koegel C, Bard M:
Sequencing, Disruption, and Characterization of the Candida albicans
Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in
erg6 Mutants. Antimicrobial Agents and Chemotherapy 1998, 42:1160-1167.
21. Felipe MS, Andrade RV, Arraes FB, Nicola AM, Maranhão AQ, Torres FA,
Silva-Pereira I, Poças-Fonseca MJ, Campos EG, Moraes LM, Andrade PA,
Tavares AH, Silva SS, Kyaw CM, Souza DP, Pereira M, Jesuíno RS,
Andrade EV, Parente JA, Oliveira GS, Barbosa MS, Martins NF, Fachin AL,
Cardoso RS, Passos GA, Almeida NF, Walter ME, Soares CM, Carvalho MJ,
Brígido MM, PbGenome Network: Transcriptional profiles of the human
pathogenic fungus Paracoccidioides brasiliensis in mycelium and yeast
cells. J Biol Chem 2005, 280:24706-24714.
22. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF,
Veine DM, Becker K, Schirmer RH: Thioredoxin reductase two modes of
catalysis have evolved. Eur J Biochem 2000, 267:6110-6117.
23. Arnér ES, Holmgren A: Physiological functions of thioredoxin and
thioredoxin reductase. Eur J Biochem 2000, 267:6102-6109.
24. Missall TA, Lodge JK: Thioredoxin reductase is essential for viability in the
fungal pathogen Cryptococcus neoformans. Eukaryot Cell 2005, 4:487-9.
25. Krnajski Z, Gilberger TW, Walter RD, Cowman AF, Muller S: Thioredoxin
reductase is essential for the survival of Plasmodium falciparum
erythrocytic stages. J Biol Chem 2002, 277:25970-25975.
26. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y: Transcriptional
regulation of the Staphylococcus aureus thioredoxin and thioredoxin
reductase genes in response to oxygen and disulfide stress. J Bacteriol
2004, 186:326-334.
27. Machado AK, Morgan BA, Merrill GF: Thioredoxin reductase-dependent
inhibition of MCB cell cycle box activity in Saccharomyces cerevisiae.
J Biol Chem 1997, 272:17045-17054.
28. Pearson GD, Merrill GF: Deletion of the Saccharomyces cerevisiae TRR1
gene encoding thioredoxin reductase inhibits p53-dependent reporter
gene expression. J Biol Chem 1998, 273:5431-5434.
29. Peñalva MA, Arst HN Jr: Regulation of gene expression by ambient pH in
filamentous fungi and yeasts. Microbiology and Molecular Biology Reviews
2002, 66:426-446.
30. Herranz S, Rodríguez JM, Bussink HJ, Sánchez-Ferrero JC, Arst HN Jr,
Peñalva MA, Vincent O: Arrestin-related proteins mediate pH signaling in
fungi. Proc Natl Acad Sci USA 2005, 102:12141-12146.
31. Davis D, Edwards JE Jr, Mitchell AP, Ibrahim AS: Candida albicans RIM101
pH response pathway is required for host-pathogen interactions. Infect
Immun 2000, 68:5953-5959.
32. Lussier M, Sdicu AM, Ketela T, Bussey H: Localization and targeting of the
Saccharomyces cerevisiae Kre2p/Mnt1p alpha 1,2-mannosyltransferase to
a medial-Golgi compartment. J Cell Biol 1995, 131:913-927.
33. Häusler A, Ballou L, Ballou CE, Robbins PW: Yeast glycoprotein
biosynthesis: MNT1 encodes an alpha-1,2-mannosyltransferase involved
in O-glycosylation. Proc Natl Acad Sci USA 1992, 89:6846-6850.
34. Hill K, Boone C, Goebl M, Puccia R, Sdicu AM, Bussey H: Yeast KRE2 Defines
a New Gene Family Encoding Probable Secretory Proteins, and Is
Required for the Correct N-Glycosylation of Proteins. Genetics 1992,
130:273-283.
35. Lussier M, Sdicu AM, Bussereau F, Jacquet M, Bussey H: The Ktr1p, Ktr3p,
and Kre2p/Mnt1p mannosyltransferases participate in the elaboration of
yeast O- and N-linked carbohydrate chains. The Journal of Biological
Chemistry 1997, 272:15527-15531.
36. Wagener J, Echtenacher B, Rohde M, Kotz A, Krappmann S, Heesemann J,
Ebel F: The putative alpha-1,2-mannosyltransferase AfMnt1 of the
Abadio et al. BMC Genomics 2011, 12:75
http://www.biomedcentral.com/1471-2164/12/75
Page 9 of 10opportunistic fungal pathogen Aspergillus fumigatus is required for cell
wall stability and full virulence. Eukaryot Cell 2008, 7:1661-1673.
37. Munro CA, Bates S, Buurman ET, Hughes HB, Maccallum DM, Bertram G,
Atrih A, Ferguson MA, Bain JM, Brand A, Hamilton S, Westwater C,
Thomson LM, Brown AJ, Odds FC, Gow NA: Mnt1p and Mnt2p of Candida
albicans are partially redundant alpha-1,2-mannosyltransferases that
participate in O-linked mannosylation and are required for adhesion
and virulence. J Biol Chem 2005, 280:1051-1060.
38. McCammon MT, Hartmann Ma, Bottema CD, Parks LW: Sterol methylation
in Saccharomyces cerevisiae. Journal of bacteriology 1984, 157:475-483.
39. Natter K, Leitner P, Faschinger A, Wolinski H, McCraith S, Fields S,
Kohlwein SD: The spatial organization of lipid synthesis in the yeast
Saccharomyces cerevisiae derived from large scale green fluorescent
protein tagging and high resolution microscopy. Mol Cell Proteomics
2005, 4:662-672.
40. Nes WD, Janssen GG, Bergenstrahle A: Structural requirements for
transformation of substrates by the (S)-adenosyl-L-methionine:delta 24
(25)-sterol methyl transferase. J Biol Chem 1991, 266:15202-15212.
41. Gaber RF, Copple DM, Kennedy BK, Vidal M, Bard M: The yeast gene ERG6
is required for normal membrane function but is not essential for
biosynthesis of the cell-cycle-sparking sterol. Molecular and Cellular
Biology 1989, 9:3447-3456.
42. Zweytick D, Leitner E, Kohlwein SD, Yu C, Rothblatt J, Daum G:
Contribution of Are1p and Are2p to steryl ester synthesis in the yeast
Saccharomyces cerevisiae.. Eur J Biochem 2000, 267:1075-1082.
43. Young LY, Hull CM, Heitman J: Disruption of ergosterol biosynthesis
confers resistance to amphotericin B in Candida lusitaniae.. Antimicrob
Agents Chemother 2003, 47:2717-2724.
44. Veine DM, Mulrooney SB, Wang PF, Williams CH Jr: Formation and
properties of mixed disulfides between thioredoxin reductase from
Escherichia coli and thioredoxin: evidence that cysteine-138 functions to
initiate dithiol-disulfide interchange and to accept the reducing
equivalent from reduced flavin. Protein Sci 1998, 7:1441-50.
45. Zhang Z, Bao R, Zhang Y, Yu J, Zhou CZ, Chen Y: Crystal structure of
Saccharomyces cerevisiae cytoplasmic thioredoxin reductase Trr1 reveals
the structural basis for species-specific recognition of thioredoxin.
Biochim Biophys Acta 2009, 1794:124-128.
46. Thomson LM, Bates S, Yamazaki S, Arisawa M, Aoki Y, Gow NA: Functional
characterization of the Candida albicans MNT1 mannosyltransferase
expressed heterologously in Pichia pastoris.. J Biol Chem 2000,
275:18933-8.
47. Lobsanov YD, Romero PA, Sleno B, Yu B, Yip P, Herscovics A, Howell PL:
Structure of Kre2p/Mnt1p: a yeast alpha1,2-mannosyltransferase
involved in mannoprotein biosynthesis. J Biol Chem 2004,
279:17921-17931.
48. Nes WD, McCourt BS, Zhou W, Ma J, Marshall JA, Peek LA, Brennan M:
Overexpression, purification, and stereochemical studies of the
recombinant (S)-adenosyl-L-methionine: D24(25)- to D24(28)-sterol
methyl transferase enzyme from Saccharomyces cerevisiae.. Arch Biochem
Biophys 1998, 353:297-311.
49. Nes WD, Marshall JA, Jia Z, Jaradat TT, Song Z, Jayasimha P: Active site
mapping and substrate channeling in the sterol methyltransferase
pathway. J Biol Chem 2002, 277:42549-56.
50. Nes WD, McCourt BS, Marshall JA, Ma J, Dennis AL, Lopez M, Li H, He L:
Site-directed mutagenesis of the sterol methyl transferase active site
from Saccharomyces cerevisiae results in formation of novel 24-ethyl
sterols. J Org Chem 1999, 64:1535-1542.
51. Nes WD: Enzyme redesign and interactions of substrate analogues with
sterol methyltransferase to understand phytosterol diversity, reaction
mechanism and the nature of the active site. Biochem Soc Trans 2005,
33:1189-1196.
52. Ganapathy K, Jones CW, Stephens CM, Vatsyayan R, Marshall JA, Nes WD:
Molecular probing of the Saccharomyces cerevisiae sterol 24-C
methyltransferase reveals multiple amino acid residues involved with
C2-transfer activity. Biochim Biophys Acta 2008, 1781:344-351.
53. Teixeira MM, Theodoro RC, de Carvalho MJ, Fernandes L, Paes HC, Hahn RC,
Mendoza L, Bagagli E, San-Blas G, Felipe MS: Phylogenetic analysis reveals
a high level of speciation in the Paracoccidioides genus. Mol Phylogenet
Evol 2009, 52:273-83.
54. Cavasotto CN, Phatak SS: Homology modeling in drug discovery: current
trends and applications. Drug Discov Today 2009, 14:676-683.
55. Marshall GR: Introduction to cheminformatics in drug discovery -
A personal view. In Chemioinformatics in drug discovery. Volume 23. Edited
by: Tudor I. Oprea, Weinhein: WILEY-VHC; 2004, ISBN: 3-527-30753-2.
56. Dai S, Saarinen M, Ramaswamy S, Meyer Y, Jacquot JP, Eklund H: Crystal
Structure of Arabidopsis thaliana NADPH Dependent Thioredoxin
Reductase at 2.5 Å Resolution. J Mol Biol 1996, 264:1044-1057.
57. Oliveira MA, Discola KF, Alves SV, Medrano FJ, Guimarães BG, Netto LES:
Insights into the specificity of thioredoxin reductase-thioredoxin
interactions. A structural and functional investigation of the yeast
thioredoxin system. Biochemistry 2010, 49:3317-3326.
58. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix
choice. Nucleic Acids Res 1994, 22:4673-80.
59. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999,
41:95-98.
60. Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference
under mixed models. Bioinformatics 2003, 19:1572-4.
61. Jones DT, Taylor WR, Thornton JM: The Rapid Generation of Mutation
Data Matrices from Protein Sequences. Comput Applic Biosci 1992,
8:275-282.
doi:10.1186/1471-2164-12-75
Cite this article as: Abadio et al.: Comparative genomics allowed the
identification of drug targets against human fungal pathogens. BMC
Genomics 2011 12:75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Abadio et al. BMC Genomics 2011, 12:75
http://www.biomedcentral.com/1471-2164/12/75
Page 10 of 10